Drug shows promise for the first time against metastatic melanoma of the eye
(Columbia University Medical Center) For the first time, a therapy has been found that can delay progression of metastatic uveal melanoma, a rare and deadly form of melanoma of the eye. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - June 19, 2014 Category: Biology Source Type: news
Selumetinib Yields Modest Benefits in Rare Eye CancerSelumetinib Yields Modest Benefits in Rare Eye Cancer
The first randomized controlled trial of the MEK inhibitor selumetinib finds modest improvement in clinical outcomes of advanced uveal melanoma but high rates of adverse effects. Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - June 17, 2014 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
Study compares survival for treatments of uncommon eye cancer
(The JAMA Network Journals) In patients with advanced uveal melanoma, treatment with the agent selumetinib, compared with chemotherapy, resulted in an improved cancer progression-free survival time and tumor response rate, but no improvement in overall survival, according to a study in the June 18 issue of JAMA. The modest improvement in clinical outcomes was accompanied by a high rate of adverse events. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - June 17, 2014 Category: Cancer & Oncology Source Type: news
Animal Trials Show Promise for Treating Eye Cancer
Researchers target genetic mutations common among uveal melanoma patients (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - May 29, 2014 Category: Cancer & Oncology Authors: webmaster at doctorslounge.com Tags: Nursing, Oncology, Ophthalmology, Research, News, Source Type: news
Melanoma of the eye caused by two gene mutations
A therapeutic target for treating the most common form of eye cancer in adults has been identified by researchers. They have also, in experiments with mice, been able to slow eye tumor growth with an existing FDA-approved drug. The researchers looked specifically at uveal melanoma. Uveal collectively refers to parts of the eye, notably the iris, that contain pigment cells. As with melanoma skin cancer, uveal melanoma is a malignancy of these melanin-producing cells. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - May 29, 2014 Category: Science Source Type: news
For Ocular Melanoma Mets to Liver, Fotemustine DisappointsFor Ocular Melanoma Mets to Liver, Fotemustine Disappoints
For patients with uveal melanoma (UM) metastases in the liver, response rates and progression-free survival are only slightly better if fotemustine is given through the hepatic artery rather then intravenously, new data show. Reuters Health Information (Source: Medscape Ophthalmology Headlines)
Source: Medscape Ophthalmology Headlines - March 27, 2014 Category: Opthalmology Tags: Hematology-Oncology News Source Type: news
Surgical Management of Posterior Uveal MelanomaSurgical Management of Posterior Uveal Melanoma
Uveal melanoma is the most common primary malignancy of the eye in adults and affects approximately 4 people per million in the US each year. Find out how globe-salvaging treatment and more are improving outcomes. Expert Review of Ophthalmology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - October 24, 2013 Category: Consumer Health News Tags: Ophthalmology Journal Article Source Type: news
Castle Biosciences launches tissue repository for eye cancer patients
Castle Biosciences Inc. has announced the availability of a tumor tissue repository for patients whose tumors are being tested with the Company's gene test for uveal, or ocular, melanoma. Patients will now have the option of storing an additional sample of their tumor free of charge for up to five years, and will be able to access it to take advantage of future developments in the disease. Castle Biosciences would provide the samples to third parties only with permission of the patient for legitimate research, treatment guidance or diagnostic purposes... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - October 2, 2013 Category: Consumer Health News Tags: Eye Health / Blindness Source Type: news
Palladium-103 Radiation Effective for Small Choroidal MelanomaPalladium-103 Radiation Effective for Small Choroidal Melanoma
Palladium-103 plaque radiation therapy was effective for treating small choroidal melanomas in a retrospective study. Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 25, 2013 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
In Metastatic Uveal Melanoma, New Drug Improves Progression-Free Survival, Shrinks Tumors
The experimental drug selumetinib is the first targeted therapy to demonstrate significant clinical benefit for patients with metastatic uveal melanoma, according to new Memorial Sloan-Kettering Cancer Center research presented at the 49th annual meeting of the American Society of Clinical Oncology (ASCO). The findings are potentially practice-changing for a historically "untreatable disease... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - June 4, 2013 Category: Consumer Health News Tags: Melanoma / Skin Cancer Source Type: news
First Drug To Help Melanoma Of The Eye
AstraZeneca's experimental drug, selumetinib, is the first targeted medication to show a significant clinical benefit for patients with melanoma of the eye (metastatic uveal melanoma), researchers from the Memorial Sloan-Kettering Cancer Center explained at the 49th annual meeting of the American Society of Clinical Oncology (ASCO), in Chicago, Illinois. The scientists say that their findings will probably change clinical practice for patients with metastatic uveal melanoma, which to date has been an "untreatable disease"... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - June 2, 2013 Category: Consumer Health News Tags: Melanoma / Skin Cancer Source Type: news
ASCO: Rare Eye Cancer Yields to Targeted Drug
CHICAGO (MedPage Today) -- The novel kinase inhibitor selumetinib may be the first treatment to shrink advanced uveal melanoma, based on phase II trial results. (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - June 2, 2013 Category: Hematology Source Type: news
Breakthrough in Rare Cancer: First Drug Works Uveal MelanomaBreakthrough in Rare Cancer: First Drug Works Uveal Melanoma
For the first time, a systemic therapy has shown clinical activity in a rare eye cancer, metastatic uveal melanoma, for which there is no standard treatment. Medscape Medical News (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - June 1, 2013 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
Breakthrough in Rare Eye Cancer: First Drug That WorksBreakthrough in Rare Eye Cancer: First Drug That Works
For the first time, a systemic therapy has shown clinical activity in a rare eye cancer, metastatic uveal melanoma, for which there is no standard treatment. Medscape Medical News (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - June 1, 2013 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
New drug improves progression-free survival, shrinks tumors in rare cancer for first time
(Memorial Sloan-Kettering Cancer Center) The experimental drug selumetinib is the first targeted therapy to demonstrate significant clinical benefit for patients with metastatic uveal melanoma, according to new Memorial Sloan-Kettering Cancer Center research presented on Saturday, June 1, at the 49th annual meeting of the American Society of Clinical Oncology. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - June 1, 2013 Category: Global & Universal Source Type: news
